OncoMatch/Clinical Trials/NCT06815029
Intracranial Genetically Modified Immune Cells (TGFβR2KO/IL13Rα2 CAR T-Cells) for the Treatment of Recurrent or Progressive Glioblastoma or Grade 3 or 4 IDH-Mutant Astrocytoma
Is NCT06815029 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies Chimeric Antigen Receptor T-Cell Therapy for recurrent astrocytoma, idh-mutant, grade 3.
Treatment: Chimeric Antigen Receptor T-Cell Therapy — This phase I trial tests the safety, side effects and best dose of TGFβR2KO/IL13Rα2 chimeric antigen receptor (CAR) T-cells given within the skull (intracranial) in treating patients with glioblastoma or IDH-mutant grade 3 or 4 astrocytoma that has come back after a period of improvement (recurrent) or that is growing, spreading, or getting worse (progressive). CAR T-cell therapy is a type of treatment in which a patient's T cells (a type of immune system cell) are changed in the laboratory so they will attack tumor cells. T cells are taken from a patient's blood. When the cells are taken from the patient's own blood, it is known as autologous. Then the gene for special receptors that bind to a certain proteins on the patient's tumor cells are added to the T cells in the laboratory. The special receptors are called CAR. Large numbers of the CAR T cells are grown in the laboratory and given to the patient by infusion for treatment of certain tumors. Giving TGFβR2KO/IL13Rα2 CAR T cells may be safe, tolerable, and/or effective in treating patients with recurrent or progressive glioblastoma or grade 3 or 4 IDH-mutant astrocytoma.
Check if I qualifyExtracted eligibility criteria
Cancer type
Glioblastoma
Biomarker criteria
Required: IDH1 mutation
Required: IL13RA2 overexpression (h-score ≥ 80)
Disease stage
Required: Stage GRADE 3, GRADE 4 (WHO CNS)
grade 3 or 4 IDH-mutant astrocytoma or glioblastoma; radiographic evidence of recurrence/progression of measurable disease
Prior therapy
Must have received: radiation therapy — front-line
radiographic evidence of recurrence/progression of measurable disease after standard therapy, and ≥ 12 weeks after completion of front-line radiation therapy
Cannot have received: bevacizumab (bevacizumab)
participants who require active bevacizumab therapy at the time of enrollment are excluded
Lab requirements
Blood counts
WBC > 2000/dl (or ANC ≥ 1,000/mm^3); Platelets ≥ 75,000/mm^3; Hemoglobin ≥ 8g/dl
Kidney function
Serum creatinine ≤ 1.6 mg/dL
Liver function
Total bilirubin ≤ 1.5 x ULN; AST ≤ 2.5 x ULN; ALT ≤ 2.5 x ULN
WBC > 2000/dl (or ANC ≥ 1,000/mm^3); Platelets ≥ 75,000/mm^3; Hemoglobin ≥ 8g/dl; Total bilirubin ≤ 1.5 x ULN; AST ≤ 2.5 x ULN; ALT ≤ 2.5 x ULN; Serum creatinine ≤ 1.6 mg/dL; O2 saturation ≥ 95% on room air
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- City of Hope Medical Center · Duarte, California
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify